Clinical Trial Detail

NCT ID NCT01774851
Title A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Merrimack Pharmaceuticals
Indications

gastric adenocarcinoma

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

MM-111 + Paclitaxel + Trastuzumab

Paclitaxel + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST